ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO413

Comparison of Individualized Sodium Management vs. Standard Treatment in Hemodialysis: The SODIAH Study

Session Information

Category: Dialysis

  • 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Braun, Jennifer, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Hessen, Germany
  • Pham, Ngoc, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Hessen, Germany
  • Cromm, Krister, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Hessen, Germany
  • Maierhofer, Andreas, Fresenius Medical Care Deutschland GmbH Werk Schweinfurt, Schweinfurt, Bayern, Germany
  • Stauss-Grabo, Manuela, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Hessen, Germany
Background

Conventional fluid and sodium (Na) management in dialysis patients includes adjusting dry weight based on clinical judgement and ancillary tools. An innovative approach to optimize Na management during dialysis has been developed with an automated Na control that has been evaluated in proof-of-concept studies (Kuhlmann et al.,2018; Sagova et al., 2019). However, the long-term clinical benefits were not addressed. Recently, Maduell et al. (2023) showed that automated Na control was potentially advantageous in reducing intradialytic weight gain (IDWG), improving blood pressure (BP) control, and decreasing intradialytic serum Na changes.

Methods

SODIAH (NCT06341452) is a prospective, parallel, randomized controlled trial with an intervention period of 12 weeks, to be conducted with the 6008 CareSystem (Fresenius Medical Care) in DE, CZ, ES, BE. The study will include 130 anuric HD-patients with a diffusive Na-load during standard dialysis and at least one of the following: IDWG>4% of dry weight, systolic BP (SBP)>180 mmHg, intradialytic morbid events (IMEs), and pre-dialysis fluid overload≥2.5L.
To assess variables from patients’ perspective, questionnaires covering fatigue, SBP issues, quality of life, thirst and xerostomia were included. These were translated into the local languages and culturally adapted after cognitive debriefing to ensure accuracy and cultural relevance in the target population.

Results

Our study is designed to assess the impact of Na zero-diffusive dialysis on performance indicators, particularly IDWG, intradialytic hemodynamic stability, IMEs, fluid status, and impact on symptom-related well-being of patients. Study results are planned to be reported in 2025.

Conclusion

SODIAH aims to broaden the knowledge of Na zero-diffusive dialysis and its clinical benefits. Culturally adapted questionnaires will be available in new languages supporting analysis of symptom-related well-being.

Funding

  • Commercial Support – Fresenius Medical Care